Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid
September 2013
in “
Current medicinal chemistry
”
New to Hydroquinone? There is a guide in the encyclopedia. Read the guide → Studysummary This study found that co-drugs synthesized from hydroquinone and tranexamic acid improved skin targeting and deposition, with reduced irritation and enhanced efficacy for treating hyperpigmentation. Our plain-language summary of this paper — not a Tressless recommendation.
The study synthesized two co-drugs, HAC and BAC, by conjugating hydroquinone and tranexamic acid (TXA) to improve skin targeting and reduce transdermal diffusion. These co-drugs were stable in aqueous solutions but rapidly degraded to their parent drugs in esterases and skin homogenates. In vitro tests showed that HAC and BAC increased hydroquinone skin deposition by 7.2- and 2.4-fold, respectively, and enhanced TXA deposition by 3- and 2-fold compared to their individual applications. In vivo experiments further confirmed these enhancements. The co-drugs, especially BAC, demonstrated significantly lower transdermal penetration, indicating better skin targeting. Both co-drugs showed strong affinities for the viable epidermis/dermis and utilized hair follicles as reservoirs for delivery. Daily application for 7 days did not cause skin irritation, making HAC and BAC promising candidates for treating skin hyperpigmentation.
